Latest Safety News

Newmont Corporation reported a robust second quarter in 2025, driven by higher gold prices, successful divestitures of non-core assets, and strong operational performance, reinforcing its financial strength and strategic focus.

Vection Technologies has secured $1 million in new AI contracts, including a significant third deal with Area 12 Consulting, boosting their partnership to $3.6 million in just ten weeks.

Karoon Energy reported a 25% jump in net revenue interest production for Q2 2025, driven by operational recovery and the Baúna FPSO acquisition. The company also advanced its Neon development with a significant resource upgrade.

SRJ Technologies has taken a strategic leap by acquiring a UAE entity registered with a regional National Oil Company, positioning itself for direct contracting in the Middle East energy sector. This move is supported by a recent capital raise and ongoing restructuring to sharpen its regional focus.

Fortescue Metals Group delivered record iron ore shipments in FY25 alongside a rare cost decline, while recalibrating its green energy ambitions and maintaining a strong financial position.

MAC Copper Limited delivered a standout June quarter with record daily copper output and sharply reduced costs, while advancing its strategic acquisition by Harmony Gold.

Podium Minerals has significantly expanded its Parks Reef project with a new Copper-Gold Zone resource, increasing the basket price by 18% and completing a $2.6 million oversubscribed capital raise.

Mount Gibson Iron Limited reports steady FY25 iron ore sales amid operational challenges and announces a strategic entry into gold with a 50% stake in the Central Tanami Project.

Lynas Rare Earths has achieved record quarterly production of key rare earth elements and reported a strong 38% increase in sales revenue, while advancing its Mt Weld expansion and signing strategic MOUs in Malaysia.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Talius Group has reported a net profit of $0.37 million for Q2 2025, driven by a 6% increase in subscriptions and strategic partnerships that expand its market reach in aged care technology.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.